Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
Breast Tissue Biomarkers Predicting Short Term Risk of Breast Cancer
Study Type: Screening
Phase: N/A
NCTID: NCT00291096
Principal Investigator:
Carol Fabian
A Phase I, First-in-Human Study of MEN2312, a KAT6 inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer
Study Type: Treatment
Phase: I
NCTID: NCT06638307
Principal Investigator:
Priyanka Sharma
Conformal Ablative Radiotherapy in Older Women CARMEN with Breast Cancer Undergoing Non-Operative Management
Study Type: Treatment
Phase: II
NCTID: NCT07242118
Principal Investigator:
Ryan Morse
OPTIMICE-PCR: De-Escalation Of Therapy In Early-Stage TNBC Patients Who Achieve PCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy
Study Type: Treatment
Phase: III
NCTID: NCT05812807
Principal Investigator:
Priyanka Sharma
ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy with HER2 Blockade
Study Type: Treatment
Phase: III
NCTID: NCT06876714
Principal Investigator:
Yiduo Hu
Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer SCARLET, A Randomized Phase III Study
Study Type: Treatment
Phase: III
NCTID: NCT05929768
Principal Investigator:
Priyanka Sharma
A Phase Ib/II Trial of Zunsemetinib in Combination with Capecitabine in Patients with Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer with Bone Metastasis
Study Type: Treatment
Phase: I/II
NCTID: NCT06374459
Principal Investigator:
Qamar Khan
Phase IIA Trial of Acolbifene 20 mg vs Low Dose Tamoxifen 5 mg in Pre-menopausal Women at High Risk for Development of Breast Cancer
Study Type: Prevention
Phase: II
NCTID: NCT05941520
Principal Investigator:
Carol Fabian
A Phase III Open-label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative HR+/HER2- Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment with a CDK4/6 Inhibitor
Study Type: Treatment
Phase: III
NCTID: NCT06982521
Principal Investigator:
Yiduo Hu
Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer
Study Type: Treatment
Phase: III
NCTID: NCT03488693
Principal Investigator:
Julia White